Call to Speedy Action regarding Covid-19 testing to drive the demand for Covid-19 Saliva-based Screening
Saliva-based screening approaches are being adopted due to challenges faced on the account of scalability and timeline related to molecular swab-based SARS-CoV-2 testing. The latest development in this regard is tabling of fluorescence-labeled antigen/antibodies testing pandemic defense platform. Persistence Market Research has walked through the intricacies related to this trending topic in its market study entitled “Covid-19 Saliva-based Screening Market”.
The Ongoing Trend
Extensive research is being conducted with regards to Covid-19 saliva-based screening. Along these lines, George Mason University, in February 2021, did initiate Covid-19 testing by making use of Fluidigm Corporation’s Advanta Dx SARS-CoV-2 RT-PCR Assay. Also, Quidel Corporation, in April 2021, did ink a distribution agreement with McKesson Corporation for improvising on availability of the household Covid-19 testing services. These findings have been tabled by Persistence Market Research, along with the probable steps from the future perspective in its latest market study entitled “Covid-19 Saliva-based Screening Market”.
Covid-19 Saliva-based Screening Market Dynamics
Product wise, the global Covid-19 saliva-based screening market spans saliva collection kits, saliva nucleic acid purification kits, and saliva-based detection kits (PCR-based kits and rapid test kits). Technology-wise, it’s RT-qPCR, lateral flow assays, and direct sample to PCR. By application, it’s diagnostics and research. By end-user, it’s home care settings, long term care facilities, biopharma companies, academic and research institutes, hospitals & clinics, and diagnostic laboratories. Persistence market Research has given proper details with insights herein in its latest market study entitled “Covid-19 saliva-based screening market”.
Get To Know More – https://www.persistencemarketresearch.com/samples/32712
What about analysis Region-wise?
North America holds the largest market share due to the US launching numerous new-fangled products through start-ups. Europe stands second due to the EMA (European Medicines Agency) granting approvals to several companies to market the products in this region. Heathrow Airport, in September 2020, did try out lateral-flow saliva testing strip from Mologic to screen passengers. However, the Asia-Pacific is expected to grow at the fastest rate in Covid-19 saliva-based screening market with the densely populated regions herein being in utmost need of Covid-19 testing. Persistence Market Research, through its latest market study entitled “Covid-19 Saliva-based Screening Market”, has entailed these.
The Zeal called “Competition”
Persistence Market Research has profiled the Covid-19 Saliva-based Screening market as Thermo Fisher Scientific, Qiagen, Hologic, Takara Bio Inc., Arcis Biotechnology Ltd., GeneProof, Abacus ALS, Chai Inc., Kolplast Group, Lucence Health Inc., Vitagene, Therma Bright Inc., ACON Laboratories, Inc., TODA Pharma, Norgen Biotek Corp., Assure tech. (Hangzhou) Co., Ltd., Beijing Hotgen Biotech Co., Ltd., Nantong Diagnos Biotechnology Co., Ltd., NeuMoDx Molecular, Inc., KYODO International Inc., Canvax, Zymo Research Corporation, Salimetrics, NEST Scientific USA, Miraclean Technology Co. Ltd., Mawi DNA Technologies, and Cell Projects Ltd.
Coming to developments, Persistence Market Research has mentioned about Abbott launching ID NOW in March 2020. It comes across as a molecular POCT to detect Covid-19. The US FDA has authorized it for EUA (Emergency Use Authorization). It gives positive results within 5 minutes, whereas negative results get delivered within 13 minutes. EUA was also obtained for an in-licensed rapid POCT for Covid-19. It was launched by Chembio Diagnostics, Inc.
With Covid-19 and its remedy being a hot potato in the current scenario the demand for Covid-19 saliva-based screening is expected to promulgate in the upcoming period.